OpenLB
Open Library of Bioscience

Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies.

Abstract

No abstract text available.

References

1. Westra J, Rondaan C, van Assen S, Bijl M (2015) Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 11:135–145 [DOI: 10.1038/nrrheum.2014.206]
2. Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, Pineda C, Vizzotti C (2018) Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol 24:138–147 [DOI: 10.1097/RHU.0000000000000624]
3. Weycker D, Farkouh RA, Strutton DR et al (2016) Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res 16:182 [DOI: 10.1186/s12913-016-1432-4]
4. World Health Organization (2008) Position paper on 23-valent pneumococcal polysaccharide vaccine. Wkly Epidemiol Rec 83:373–384
5. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2014) Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 32:2364–2374. https://doi.org/10.1016/j.vaccine.2014.02.002 [DOI: 10.1016/j.vaccine.2014.02.002]
6. Jackson LA, Gurtman A, van Cleeff M et al (2013) Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31:3594–3602. https://doi.org/10.1016/j.vaccine.2013.04.084 [DOI: 10.1016/j.vaccine.2013.04.084]
7. Lesprit P, Pédrono G, Molina JM et al (2007) Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 21:2425–2434. https://doi.org/10.1097/QAD.0b013e3282887e91 [DOI: 10.1097/QAD.0b013e3282887e91]
8. Centers for Disease Control and Prevention (CDC) (2012) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 61:816–819
9. Vieira de Rezende RP, Mattos GA, de Mello Leal Augusto R, Machado Gayer CR, Mendes Klumb E (2019) Predictors for seasonal influenza vaccination and reasons for inadequate vaccination coverage against a broad spectrum of vaccine-preventable diseases: a cross-sectional study among a Brazilian cohort of adult patients with systemic lupus erythematosus. Lupus 28:794–796. https://doi.org/10.1177/0961203319846383 [DOI: 10.1177/0961203319846383]
10. Centers for Disease Control and Prevention (CDC) (2008) Progress in introduction of pneumococcal conjugate vaccine—worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep 57:1148–1151
11. Ministério da Saúde (2019) Manual dos Centros de Referência para Imunobiológicos especiais (5ª edição). Ministério da Saúde https://sbim.org.br/images/calendarios/manual-centros-referencia_imunobiologicos-especiais-5ed-web.pdf Accessed on Dec 15, 2019
12. World Health Organization (1993) International classification of diseases and related health problems, tenth revision: volume 2, instruction manual. World Health Organization, Geneva
13. Sartori Vieira C, de Rezende RPV, Mendes Klumb E, Cardoso Mocarzel LO, Altenburg Gismondi R (2019) Mortality profile related to the spectrum of systemic connective tissue diseases: a retrospective, population-based, case-control study. Lupus 28:1498–1500 [DOI: 10.1177/0961203319876993]

MeSH Term

Chemicals